Back to discover

Protein / target

Signal transducer and activator of transcription 6

Encoded bySTAT6P42226Homo sapiensSwiss-Prot
UniProt: P42226Ensembl: ENSG00000166888HGNC: HGNC:11368NCBI Gene: 6778
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

DNA-binding transcription factor

Strongest disease association

Asthma

Via encoding gene STAT6 · Genetic evidence · score 0.74

Research activity

Emerging research

1 papers · latest 2020

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Carries out a dual function: signal transduction and activation of transcription.

View complete UniProt function annotation

Carries out a dual function: signal transduction and activation of transcription. Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signaling

Subcellular location

CytoplasmNucleus
Domains and Gene Ontology detail (26)

Domains & features

SH2

Gene Ontology

  • Cchromatin
  • Ccytoplasm
  • Ccytosol
  • Cnucleoplasm
  • Cnucleus
  • CRNA polymerase II transcription regulator complex
  • FDNA-binding transcription activator activity, RNA polymerase II-specific
  • FDNA-binding transcription factor activity
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • Fidentical protein binding
  • Fprotein phosphatase binding
  • FRNA polymerase II cis-regulatory region sequence-specific DNA binding

847 aa · 94 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOTranscriptional regulationUniProt · GOImmune signallingUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·regulation of cell population proliferation

Transcriptional regulation

  • ·Carries out a dual function: signal transduction and activation of transcription. Involv…
  • ·RNA polymerase II transcription regulator complex
  • ·DNA-binding transcription activator activity, RNA polymerase II-specific
  • ·DNA-binding transcription factor activity

Immune signalling

  • ·Carries out a dual function: signal transduction and activation of transcription. Involv…
  • ·cytokine-mediated signaling pathway
  • ·interleukin-4-mediated signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene STAT6

Gene-level evidence surfaced through the gene STAT6 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Asthma
0.76Well supported

Genetic evidence dominant · Open Targets 0.47

Hypersensitivity
0.71Moderately supported

Genetic evidence dominant · Open Targets 0.43

Respiratory Tract Diseases
0.67Moderately supported

Genetic evidence dominant · Open Targets 0.41

Rhinitis, Allergic
0.66Moderately supported

Genetic evidence dominant · Open Targets 0.40

Lymphoma
0.45Limited support

Somatic mutation evidence dominant · Open Targets 0.39

View evidence synthesis (5)
AsthmaWell supported
0.76
agreement 0.62–0.90
Genetic92%Literature8%

Open Targets aggregate 0.47 · 2 independent evidence families

HypersensitivityModerately supported
0.71
agreement 0.57–0.85
Genetic93%Literature7%

Open Targets aggregate 0.43 · 2 independent evidence families

Respiratory Tract DiseasesModerately supported
0.67
agreement 0.53–0.81
Genetic97%Literature3%

Open Targets aggregate 0.41 · 2 independent evidence families

Rhinitis, AllergicModerately supported
0.66
agreement 0.52–0.80
Genetic92%Literature8%

Open Targets aggregate 0.40 · 2 independent evidence families

LymphomaLimited support
0.45
agreement 0.29–0.61
Somatic mutation80%Literature20%

Open Targets aggregate 0.39 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Asthma0.47
Lymphoma, Large B-Cell, Diffuse0.44
Hypersensitivity0.43
Respiratory Tract Diseases0.41
Rhinitis, Allergic0.40
Lymphoma0.39

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2020

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.259 cites

Furue M · International journal of molecular sciences · 2020

Recent

Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.

Furue M · International journal of molecular sciences · 2020

Europe PMC papers linked directly to this protein.